NEW YORK (GenomeWeb News) – Molecular Diagnostics firm GenomeDx said today it has entered into agreements to provide laboratory testing as a participating provider with three preferred provider networks.

The PPOs are Stratose, Three Rivers Provider network, and Fortified Provider Network. The deals expand the number of covered lives with access to GenomeDx's Decipher prostate cancer classifier test by 62.6 million, the San Diego-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.